EPO, short for erythropoietin, is a hormone your body naturally produces to stimulate red blood cell production. The synthetic version is a prescription drug used to treat anemia in people with kidney disease, cancer patients on chemotherapy, and certain HIV treatments. It’s also one of the most well-known performance-enhancing drugs in endurance sports, where athletes use it illegally to boost oxygen-carrying capacity.
How Your Body Makes EPO Naturally
Your kidneys are the primary source of natural erythropoietin. Specialized cells nestled around tiny blood vessels deep in the kidney tissue produce and release EPO when they detect low oxygen levels in the blood. This is why kidney disease so often leads to anemia: damaged kidneys can’t produce enough EPO to keep red blood cell levels where they should be.
Once released into the bloodstream, EPO travels to bone marrow and locks onto receptors on the surface of immature red blood cell precursors. This triggers a chain reaction inside those cells that does several things at once: it prevents the young cells from dying off prematurely, it ramps up their division and maturation, and it increases iron uptake so the cells can build hemoglobin, the protein that carries oxygen. EPO even stimulates production of a hormone called erythroferrone, which tells the liver to release more stored iron into the bloodstream so there’s enough raw material for all those new red blood cells.
Medical Uses of Synthetic EPO
The FDA has approved synthetic EPO for several conditions. The most common is anemia caused by chronic kidney disease, whether the patient is on dialysis or not. It’s also approved for anemia from chemotherapy, for certain HIV-related treatments that suppress red blood cell production, and to reduce the need for blood transfusions during and after major surgeries.
Two main versions exist. The original form, epoetin alfa (sold as Procrit and Epogen), has a relatively short duration in the body and typically needs to be given two or three times per week. A newer version, darbepoetin alfa (sold as Aranesp), was engineered with extra sugar molecules on its surface that slow its breakdown, allowing it to be given just once a week or even every two weeks. In clinical trials comparing the two in dialysis patients, the once-weekly darbepoetin maintained the same red blood cell levels as epoetin alfa given three times weekly. That cuts annual injections from around 156 to 52, which makes a meaningful difference for patients who are already managing the demands of dialysis.
Both forms can be given intravenously or by injection under the skin. The subcutaneous route tends to require lower doses overall, though the exact dose is always adjusted based on how an individual patient responds and their iron levels.
Risks and Side Effects
Synthetic EPO carries serious cardiovascular risks, particularly when it pushes red blood cell levels too high. More red blood cells mean thicker blood, and thicker blood increases vascular resistance. Population studies have found that hypertension prevalence doubles in people whose red blood cell concentration is elevated by as little as 10 percentage points. In clinical use, higher target hemoglobin levels are consistently linked to greater rates of heart attack, stroke, heart failure, and blood clots.
The FDA requires all EPO drugs to be prescribed under a formal risk management program. For cancer patients, the warnings are especially stark: multiple clinical trials have shown that EPO use can accelerate tumor growth, increase the chance of relapse, and shorten survival. In one study of metastatic breast cancer patients, those receiving EPO had decreased 12-month survival. In early breast cancer, EPO use was linked to worse relapse-free and overall survival at three years. A head and neck cancer study targeting hemoglobin levels above 14 or 15 g/dL found decreased five-year survival. Because of these findings, the general principle is to use the lowest effective dose and only when the goal is to avoid blood transfusions, not to normalize hemoglobin completely.
EPO in Sports Doping
EPO became the drug of choice in endurance sports because it directly increases the blood’s oxygen-carrying capacity. A systematic review of controlled studies found that synthetic EPO significantly raises both red blood cell concentration and hemoglobin levels compared to placebo, with effects appearing across low, medium, and high doses. It also improves maximal oxygen consumption (VO2 max), the gold standard measure of aerobic fitness, at all dose levels studied. These gains translate to higher peak power output and longer time to exhaustion.
There’s an important caveat, though. The performance improvements show up almost exclusively at maximal exercise intensities in lab settings. At submaximal efforts, which more closely resemble the sustained pace of actual competition, the benefits are less clear. Low-dose EPO did not significantly improve submaximal oxygen use compared to placebo.
The dangers for athletes mirror the medical risks but are amplified by the lack of medical supervision. During intense exercise, dehydration further concentrates already-thickened blood, compounding the risk of clots, stroke, and cardiac events. Several sudden deaths among professional cyclists in the late 1980s and 1990s were widely attributed to EPO use, though proving a direct link is difficult after the fact.
How Anti-Doping Agencies Detect It
Detecting EPO doping relies on two complementary approaches: direct urine testing and longitudinal blood monitoring. Urine tests can identify the synthetic form of EPO directly, but their sensitivity depends heavily on timing. If enough time passes between the last injection and the test, the drug clears the system while its effects on red blood cells persist.
The more powerful tool is the Athlete Biological Passport (ABP), introduced by the World Anti-Doping Agency in 2009. Rather than looking for the drug itself, the ABP tracks each athlete’s blood values over time, building an individualized profile of hemoglobin, reticulocyte percentage (a marker of new red blood cell production), and a calculated score combining the two. Any values that fall outside an athlete’s established normal range, calculated at a 99.7% confidence interval, raise a flag. In controlled studies where researchers knew which subjects had used EPO, the ABP correctly identified 91.3% of doping cases, with near-perfect specificity, meaning almost no false positives. Abnormal passport readings can trigger targeted urine testing or serve as a doping violation on their own.
The ABP’s strength is that it doesn’t depend on catching athletes at the exact moment a drug is in their system. Because it tracks the downstream effects of blood manipulation over months or years, it’s harder to evade than a single-sample urine test. Still, roughly 9% of users in the controlled study went undetected, so the system isn’t foolproof.